Clinical Trial Detail

NCT ID NCT02098343
Title p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246
Recruitment Completed
Gender female
Phase Phase Ib/II
Variant Requirements No
Sponsors Aprea Therapeutics AB
Indications

ovarian carcinoma

Therapies

Carboplatin + Doxorubicin

APR-246 + Carboplatin + Doxorubicin

Age Groups: adult senior

No variant requirements are available.